Table 2. Adjusted Odds Ratios.
| Variable | OR | 95% CI | p-value | ||
|---|---|---|---|---|---|
| Haloperidol–male | 0.45 | [0.28, 0.73] | 0.001 | ||
| Haloperidol–female | 1.02 | [0.71, 1.46] | 0.93 | ||
| Interaction: haloperidol, female | 2.25 | [1.25, 4.05] | 0.007 | ||
| Gender (reference: male) | 2.66 | [1.80, 3.93] | <0.001 | ||
| Smoking status (reference: non-smoker) | 0.78 | [0.54, 1.13] | 0.20 | ||
| History of PONV (reference: negative) | 1.59 | [0.82, 3.05] | 0.17 | ||
| ASA (reference: ASA 1) | 0.001a | ||||
| ASA 2 | 0.56 | [0.37, 0.86] | 0.008 | ||
| ASA 3–4 | 0.41 | [0.25, 0.66] | <0.001 | ||
| Surgical procedure (reference: Laparotomy and opening of the retroperitoneal space) | <0.001a | ||||
| Operations at the kidney | 0.74 | [0.51, 1.06] | 0.10 | ||
| Cystectomy | 1.09 | [0.41, 2.94] | 0.86 | ||
| Replacement of the urinary bladder | 0.71 | [0.35, 1.44] | 0.34 | ||
| Other operations at the urinary organs | 0.10 | [0.02, 0.45] | 0.002 | ||
| Excision and destruction of prostate tissue | 1.68 | [0.97, 2.91] | 0.06 | ||
| Radical prostatectomy | 0.64 | [0.32, 1.26] | 0.19 | ||
| Local excision and destruction of ovarial tissue | 0.25 | [0.09, 0.70] | 0.008 | ||
| Oophorectomy | 0.54 | [0.15, 1.95] | 0.35 | ||
| Hysterectomy | 0.73 | [0.46, 1.17] | 0.19 | ||
| Partial excision of the mammarian glandula and destruction of mammarian tissue | 0.50 | [0.23, 1.06] | 0.07 | ||
| Excision and resection of the mammarian glandula | 0.40 | [0.17, 0.94] | 0.04 | ||
| Combined anesthesia | 1.12 | [0.52, 2.41] | 0.77 | ||
| Age (+ 10 years) | 1.00 | [0.90, 1.11] | 0.96 | ||
| BMI (+ 5 kg/m2) | 1.08 | [0.95, 1.23] | 0.23 | ||
| Anesthesia duration | - | - | <0.001 | ||
| Sufentanil | |||||
| Intravenous (bolus, total dose) | - | - | 0.36 | ||
| Epidural | 0.03a | ||||
| 10 μg vs. none | 2.06 | [1.02, 4.16] | 0.04 | ||
| 20 μg vs. none | 5.21 | [1.48, 18.36] | 0.01 | ||
| Intravenous (infusion, continuous rate; + 25 μg) | 0.92 | [0.42, 1.99] | 0.83 | ||
| Intravenous (TCI, total dose; + 10 μg) | 1.10 | [1.00, 1.21] | 0.05 | ||
| Remifentanil | |||||
| Intravenous (bolus, + 100 μg) | 0.79 | [0.13, 4.89] | 0.80 | ||
| Intravenous (infusion, continuous rate; + 100 μg) | 1.01 | [0.98, 1.05] | 0.48 | ||
| Intravenous (TCI, total dose) | - | - | 0.20 | ||
| Piritramide | |||||
| Intravenous (total dose) | - | - | <0.001 | ||
| Sevoflurane | |||||
| Average concentration (+ 0.1 Vol%et) | 0.96 | [0.90, 1.02] | 0.15 | ||
| Max. concentration (+ 1 Vol%et) | 1.52 | [1.07, 2.16] | 0.02 | ||
| Propofol | |||||
| Intravenous (bolus; + 50 mg) | 0.96 | [0.84, 1.08] | 0.48 | ||
| Intravenous (infusion, continuous rate, mg/h) | - | - | 0.03 | ||
| Intravenous (TCI, total dose; + 200 mg) | 0.90 | [0.84, 0.96] | 0.003 |
Adjusted odds ratios (OR) with 95% confidence intervals (CI) and p-values (Wald test) computed from a multivariable logistic additive regression model which includes the interaction between haloperidol and gender.—indicates that the estimated effect is non-linear and can only be described via a graph (Fig 3).
a p-value resulting from the Wald test for testing all levels of the respective covariate.
Vol%et = Volume% endtidal.